Short answer
PepGen Inc (PEPG) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). PepGen announced third-quarter 2026 financial results for the period ended September 30, 2026.
PepGen Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- PepGen announced third-quarter 2026 financial results for the period ended September 30, 2026
- Press release highlights recent corporate developments alongside quarterly results
- Exhibit 99.1 contains the detailed financial figures and business updates investors need to assess performance
Item 7.01 · Regulation FD Disclosure
- PepGen announced positive Phase 2 FREEDOM2-DM1 results for a 10mg/kg dose
- Results reportedly showed the highest reported splicing correction in the program
- Multiple functional measures improved, potentially strengthening PEPG’s clinical and regulatory position
Item 8.01 · Other Events
- Investor presentation updates FREEDOM2-DM1 data for the 10 mg/kg multiple-ascending-dose cohort
- Materials support investor discussions and may influence views on PepGen’s DM1 clinical progress
- Detailed efficacy and safety findings appear in Exhibit 99.3
Item EX-99.1 · Exhibit EX-99.1
- 10 mg/kg cohort showed 46.5% mean splicing correction, with functional improvements across mobility, grip strength and hand opening
- Safety remained favorable: no treatment discontinuations, serious or severe adverse events, or dose-limiting toxicities at 10 mg/kg
- 12.5 mg/kg cohort fully enrolled, with results expected in 1H 2027, providing the next major clinical catalyst
- Partial FDA clinical hold remains unresolved, creating regulatory risk despite planned EOP2 discussions in 2H 2027
- Cash $104.8M supports operations into 2028, while quarterly net loss reached $19.4M and operating expenses rose to $20.4M
Item EX-99.2 · Exhibit EX-99.2
- Phase 2 10 mg/kg cohort showed 46.5% mean splicing correction at Week 13, with four of six participants exceeding 50%
- Functional gains at Week 16: vHOT improved 52.7%, grip strength 16.2%, TUG 8.5%, and 10MWRT 6.8%
- Safety profile supportive: mild or moderate adverse events only, no serious events, discontinuations, or dose-limiting toxicities
- 12.5 mg/kg cohort fully enrolled, with clinical results expected in the first half of 2027
- U.S. program remains subject to a partial clinical hold, limiting near-term regulatory flexibility
Item EX-99.3 · Exhibit EX-99.3
- 10 mg/kg cohort showed 46.5% mean splicing correction at Week 13, with 4 of 6 patients exceeding 50%
- Functional improvements at 10 mg/kg: vHOT improved 4.3 seconds at Week 13 and 3.9 seconds at Week 16
- Favorable safety profile: no serious adverse events, dose-limiting toxicities, or discontinuations among 10 mg/kg participants
- 12.5 mg/kg cohort fully enrolled, with clinical results expected in H1 2027
- Planned expansion cohort targets longer-term data up to 9 months, while FDA partial clinical hold remains a key development risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PepGen Inc 8-K filings
Get the next PEPG 8-K as it lands
Follow PEPG for push alerts, or ask the research agent what this filing means.